Caladrius Biosciences Inc is a company developing cellular therapeutics to treat certain diseases. The company has internal specialized cell therapy clinical development expertise to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in humans. The product portfolio pf the group includes, CLBS03, an ex vivo expanded polyclonal T regulatory cell therapy for the treatment of recent-onset type 1 diabetes in a enrolling Phase 2 trial.